TOP > 外国特許検索 > ANTI-ACANTHAMOEBA COMPOSITION, AND OPHTHALMIC AGENT CONTAINING SAID ANTI-ACANTHAMOEBA COMPOSITION

ANTI-ACANTHAMOEBA COMPOSITION, AND OPHTHALMIC AGENT CONTAINING SAID ANTI-ACANTHAMOEBA COMPOSITION 新技術説明会

外国特許コード F160008874
整理番号 77
掲載日 2016年10月12日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP064665
国際公開番号 WO 2014192068
国際出願日 平成25年5月27日(2013.5.27)
国際公開日 平成26年12月4日(2014.12.4)
発明の名称 (英語) ANTI-ACANTHAMOEBA COMPOSITION, AND OPHTHALMIC AGENT CONTAINING SAID ANTI-ACANTHAMOEBA COMPOSITION 新技術説明会
発明の概要(英語) [Problem] Vegetative cells of acanthamoebas are sensitive to drugs and disinfection is relative easy, but since disinfection of acanthamoebas during the cyst period is extremely difficult, the purpose of the present invention is to provide a technique relating to an anti-acanthamoeba composition having strong bactericidal action on both vegetative cells and cyst cells of acanthamoebas, and an ophthalmic agent containing said anti-acanthamoeba composition. [Solution] This anti-acanthamoeba composition contains a cationic polymer bactericidal agent and lactoferricin as active components, and this ophthalmic agent contains said anti-acanthamoeba composition.
特許請求の範囲(英語) [claim1]

(Claims machine translated from Japanese)
[claim2]
1. The cation characteristic high-molecular bactericide and that it contains lact ferri thin as the active ingredient are featured, the composition for anti- [akantoameba].
[claim3]
2. The aforementioned cation characteristic high-molecular bactericide hydrochloric acid [porihekisanido], the ***.epsilon.-pori lysine, is 1 kinds or 2 kinds or more which are chosen from the group which consists of [porikuotaniumu], in claim 1 the composition for anti- [akantoameba] of statement.
[claim4]
3. Density of the aforementioned cation characteristic high-molecular bactericide at least is 0.1ppm, in claim 1 or 2 the composition for anti- [akantoameba] of statement.
[claim5]
4. The aforementioned lact ferri thin density at least is 1.5ppm, either of the claim 1-3 in 1 sections the composition for anti- [akantoameba] of statement.
[claim6]
5. Either of the claim 1-4 the composition for anti- [akantoameba] of statement is contained in 1 sections, the medicine for ophthalmology.
[claim7]
6. In the claim 5 which is the multipurpose medicine for the contact lens the medicine for ophthalmology of statement.
[claim8]
7. In the claim 5 which is the remedy medicine of the [akantoameba] keratitis the medicine for ophthalmology of statement.
[claim9]
8. In the claim 5 which is the instillation medicine the medicine for ophthalmology of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MENICON CO., LTD.
  • TAMAGAWA K12 AND UNIVERSITY
  • MORINAGA MILK INDUSTRY CO., LTD.
  • 発明者(英語)
  • IMAYASU MASAKI
  • NOMACHI MIYA
  • TOMITA SHINICHI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close